Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI. Positive results were announced from a phase 3 study evaluating ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

Patients with Enterobacter infections experienced similar outcomes when treated with cefepime and carbapenems, according to a study in Clinical Infectious Diseases. Researchers found none of the ...

Cefepime-taniborbactam has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the U.S. Food and Drug Administration (FDA). In October 2022, BARDA awarded a contract ...

Review the side-effects of Cefepime as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

Please provide your email address to receive an email when new articles are posted on . McGovern PC, et al. Abstract 731. Presented at: IDWeek; Oct. 19- 23, 2022. Washington (hybrid meeting). A ...

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to ...

Details concerning the Cefepime combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and ...

Between January 2001 and December 2002, LACHIS provided 134 courses of long-term home antimicrobial therapy for osteomyelitis. No cases of neutropenia were reported for the 121 courses of ...